title: Light-Chain Deposition Disease Successfully Treated with Bortezomib in an Elderly Patient: A Case Report and Review of the Literature.
abstract: We herein report the case of an elderly patient with light-chain deposition disease (LCDD) successfully treated with bortezomib. An 83-year-old woman was admitted because of nephrotic syndrome. She was diagnosed to have monoclonal gammopathy of undetermined significance (IgG-κ type) and LCDD, on the basis of serum and urinary immunoelectrophoresis and renal biopsy. She responded to a modified regimen of bortezomib-based chemotherapy with disappearance of proteinuria without any adverse effects. According to a literature review of 16 cases, including the present case, bortezomib-based chemotherapy appears to be a convincing strategy for the treatment of LCDD even in elderly patients.
authors.affiliation: Division of Nephrology, Department of Medicine, Showa University School of Medicine, Japan.
authors.forename: Yukihiro
authors.initials: Y
authors.lastname: Wada
authors.forename: Masayuki
authors.initials: M
authors.lastname: Iyoda
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Saito
authors.forename: Noriko
authors.initials: N
authors.lastname: Arai-Nunota
authors.forename: Ken
authors.initials: K
authors.lastname: Iseri
authors.forename: Eiko
authors.initials: E
authors.lastname: Tomita
authors.forename: Misa
authors.initials: M
authors.lastname: Ikeda
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Yamaguchi
authors.forename: Takanori
authors.initials: T
authors.lastname: Shibata
mesh_terms: D000369:Aged, 80 and over; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D000069286:Bortezomib / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007147:Immunoglobulin Light Chains / Q000378:metabolism*; D008998:Monoclonal Gammopathy of Undetermined Significance / Q000175:diagnosis* / Q000473:pathology; D009404:Nephrotic Syndrome / Q000209:etiology* / Q000473:pathology / Q000652:urine; D011507:Proteinuria / Q000209:etiology*; D012074:Remission Induction; D016896:Treatment Outcome
chemical_list: D018906:Antineoplastic Agents, Alkylating; D007147:Immunoglobulin Light Chains; D000069286:Bortezomib